title: Response to Comment on the FLAT-SUGAR Trial Investigators. Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk. Diabetes Care 2016;39:973-981.
authors.affiliation: Division of Cardiology, University of Washington, Seattle, WA cardiac@uw.edu.
authors.forename: Kevin D
authors.initials: KD
authors.lastname: O'Brien
authors.affiliation: Division of Metabolism, Endocrinology & Nutrition, University of Washington, Seattle, WA.
authors.forename: Irl B
authors.initials: IB
authors.lastname: Hirsch
authors.affiliation: Division of Endocrinology, Diabetes & Clinical Nutrition, Oregon Health & Science University, Portland, OR.
authors.forename: Matthew C
authors.initials: MC
authors.lastname: Riddle
authors.affiliation: Division of Cardiology, University of Washington, Seattle, WA.
authors.forename: Jeffrey L
authors.initials: JL
authors.lastname: Probstfield
mesh_terms: D001786:Blood Glucose; D002318:Cardiovascular Diseases; D003924:Diabetes Mellitus, Type 2; D052216:Glucagon-Like Peptide 1; D005947:Glucose; D006801:Humans; D007004:Hypoglycemic Agents; D007328:Insulin; D061266:Insulin, Short-Acting; D012108:Research Personnel; D012307:Risk Factors; D000073893:Sugars
chemical_list: D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061266:Insulin, Short-Acting; D000073893:Sugars; D052216:Glucagon-Like Peptide 1; D005947:Glucose